Speaker
Description
Inflammation is a critical factor in a spectrum of diseases, spanning from primary immune-mediated inflammatory conditions to prevalent disorders such as cardiovascular diseases, metabolic disorders, and neurodegenerative processes. Yet, our understanding of the complex mechanisms driving immune responses remains limited, primarily due to a scarcity of cellular and molecular insights obtained in their natural context. In this context, in vivo molecular imaging emerges as an invaluable tool for elucidating information about inflammatory biomarkers, pathways, and cells. This approach not only enhances diagnostic capabilities but also facilitates the guidance and monitoring of therapeutic interventions while pinpointing novel targets for further research.
Among the array of clinically available imaging modalities, MRI stands out as the preferred choice when coupling molecular/cellular information with high spatial resolution.
This contribution seeks to offer an overview of advancements in preclinical research within this domain. Various MRI contrast modes will be explored, encompassing traditional T1 and T2 relaxation agents, cutting-edge CEST and hyperpolarized probes, and methodologies based on 19F-MRI detection. Furthermore, the potential for clinical translation of these techniques will be discussed.
